• 5. November 2024

ISA Pharmaceuticals‘ ISA101 Studied in Phase II Oropharyngeal Cancer Combination Trial at MD Anderson Cancer Center

ByISA Pharmaceuticals

Apr 26, 2018

Teile den Beitrag mit Freunden